Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide

European Journal of Clinical Pharmacology

Volumn 52, Issue 3, 1997, Pages 173-177

  Hegner, G ^a   Faust, G ^a   Freytag, F ^b   Meilenbrock, S ^c   Sullivan, J ^c   Bodin, F ^c  

^a General Hospital ^*

^b Cardiovascular Clinical Development   (Switzerland)

^c General Practice (Leipzig Dresden Duisburg Monchengladbach Stadtlengsfeld Frankfurt/Main)   (Germany)

Author keywords

Essential hypertension; Hydrochlorothiazide; Thiazide diuretic; Valsartan; angiotensin II receptor antagonist

Indexed keywords

ANGIOTENSIN ANTAGONIST; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; DYSPNEA; ESSENTIAL HYPERTENSION; FEMALE; GASTRITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0030925703     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050270     Document Type: Article

References (14)

1. Guidelines for the Management of Mild Hypertension (1989) memorandum from WHO/ISH meeting. J Hypertension 7: 689-693
2. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, et al. (1993) Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 306: 983-987
3. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee (1993) Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 307: 1541-1546
4. Fifth Report of the Joint National Committee of Detection, Evaluation, and Treatment of High Blood Pressure (JNCV) (1993) Arch Intern Med 153: 154-183
5. Boissel J-P, Collet J-P, Lion L, Ducruet T, Moleur P, Luciani J, Milon H, Madonna O, Gillet J, Gerini P, Dazord A, Haugh MC and the OCAPI Study Group (1995) A randomised comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. J Hypertension 13: 1059-1067
6. Foote EF, Halstenson CE. (1993) New therapeutic agents in the management of hypertension: angiotensin II receptor antagonists and renin inhibitors. Ann Pharmacother 27: 1495-1503.
7. Weber MA (1992) Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertension 5: 247S-251S
8. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H (1994) Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 47: 231-245
9. Criscone, Bradley, Buehlmayer, Whitebread, Glazer, Lloyd, Mueller, de Gasparo (1995) Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 13:
10. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F (1996) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther (in press)
11. McHugh RB, Le CT, (1984) Confidence estimation and size of a clinical trial. Controlled Clin Trials 5: 157-163
12. Lipsitz L (1989) Orthostatic hypotension in the elderly. N Engl J Med 321: 952-957
13. Tikkanen I, Omvik P, Jensen H (1995) Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertension. 13: 1343-1351.
14. Johnston CI (1995) Angiotensin receptor antagonists: focus on Losartan. Lancet 346: 1403-1407